Php114 - The Erratic and Long Access Journey of Orphan Drugs From Europe to Portugal

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1008
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Php325 - Orphan Drugs‘ Market Access Challenges in Europe From a German Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Mechanism of Coordinated Access to Orphan Drugs

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2012English

Psy135 - Access to Orphan Drugs – Regulation Within the European Law

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Psy150 - Inequity of Orphan Drugs Prices in Europe

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Psy131 - Access to Orphan Drugs (Od) in Spain: Analysis of Nusinersen’s Case

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The Long Journey From Diagnosis to Therapy

Annual Review of Genomics and Human Genetics
GeneticsMolecular Biology
2020English

Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries

PLoS ONE
Multidisciplinary
2015English

Are Orphan Drugs Treated the Same Across Europe: An Hta Case Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Access to Orphan Drugs: A Cross Country Comparison of Legislative Approach Among Serbia, Croati a and Macedonia

Acta Medica Medianae
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy